ROGER STEGMAN, M.D.; RAYMOND ALEXANIAN, M.D.
The frequency of solid tumors was evaluated in 628 consecutive patients with multiple myeloma who had been treated with various melphalan-prednisone combinations. Among those patients who lived at least 2 months, the incidence and diversity of second tumors were similar to those in normal persons of the same age and duration at risk. The diagnosis was usually made within 2 years after the start of chemotherapy for the myeloma. Long-term melphalan therapy did not seem to contribute to the pathogenesis of second solid tumors in patients with multiple myeloma.
Learn more about subscription options.
Register Now for a free account.
STEGMAN R, ALEXANIAN R. Solid Tumors in Multiple Myeloma. Ann Intern Med. 1979;90:780-782. doi: 10.7326/0003-4819-90-5-780
Download citation file:
Published: Ann Intern Med. 1979;90(5):780-782.
Hematology/Oncology, Multiple Myeloma.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only